These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 1674549)
1. Blocking of human immunodeficiency virus infection depends on cell density and viral stock age. Layne SP; Merges MJ; Spouge JL; Dembo M; Nara PL J Virol; 1991 Jun; 65(6):3293-300. PubMed ID: 1674549 [TBL] [Abstract][Full Text] [Related]
2. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. Moore JP; McKeating JA; Norton WA; Sattentau QJ J Virol; 1991 Mar; 65(3):1133-40. PubMed ID: 1995942 [TBL] [Abstract][Full Text] [Related]
3. Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity. Kennedy MS; Orloff S; Ibegbu CC; Odell CD; Maddon PJ; McDougal JS AIDS Res Hum Retroviruses; 1991 Dec; 7(12):975-81. PubMed ID: 1687500 [TBL] [Abstract][Full Text] [Related]
4. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. Orloff SL; Kennedy MS; Belperron AA; Maddon PJ; McDougal JS J Virol; 1993 Mar; 67(3):1461-71. PubMed ID: 8437224 [TBL] [Abstract][Full Text] [Related]
5. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. Moore JP; McKeating JA; Huang YX; Ashkenazi A; Ho DD J Virol; 1992 Jan; 66(1):235-43. PubMed ID: 1727487 [TBL] [Abstract][Full Text] [Related]
6. HIV requires multiple gp120 molecules for CD4-mediated infection. Layne SP; Merges MJ; Dembo M; Spouge JL; Nara PL Nature; 1990 Jul; 346(6281):277-9. PubMed ID: 2374593 [TBL] [Abstract][Full Text] [Related]
7. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. Dey B; Del Castillo CS; Berger EA J Virol; 2003 Mar; 77(5):2859-65. PubMed ID: 12584309 [TBL] [Abstract][Full Text] [Related]
8. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Layne SP; Merges MJ; Dembo M; Spouge JL; Conley SR; Moore JP; Raina JL; Renz H; Gelderblom HR; Nara PL Virology; 1992 Aug; 189(2):695-714. PubMed ID: 1386485 [TBL] [Abstract][Full Text] [Related]
9. Kinetics of soluble CD4 binding to cells expressing human immunodeficiency virus type 1 envelope glycoprotein. Dimitrov DS; Hillman K; Manischewitz J; Blumenthal R; Golding H J Virol; 1992 Jan; 66(1):132-8. PubMed ID: 1727475 [TBL] [Abstract][Full Text] [Related]
10. Soluble CD4-PE40 is cytotoxic for a transfected mammalian cell line stably expressing the envelope protein of human immunodeficiency virus (HIV-1), and cytotoxicity is variably inhibited by the sera of HIV-1-infected patients. Pitts TW; Bohanon MJ; Leach MF; McQuade TJ; Marschke CK; Merritt JA; Wierenga W; Nicholas JA AIDS Res Hum Retroviruses; 1991 Sep; 7(9):741-50. PubMed ID: 1742081 [TBL] [Abstract][Full Text] [Related]
11. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. Moore JP; McKeating JA; Jones IM; Stephens PE; Clements G; Thomson S; Weiss RA AIDS; 1990 Apr; 4(4):307-15. PubMed ID: 2190605 [TBL] [Abstract][Full Text] [Related]
12. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Brighty DW; Rosenberg M; Chen IS; Ivey-Hoyle M Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7802-5. PubMed ID: 1909031 [TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. McKeating JA; Cordell J; Dean CJ; Balfe P Virology; 1992 Dec; 191(2):732-42. PubMed ID: 1280382 [TBL] [Abstract][Full Text] [Related]
14. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. Sullivan N; Sun Y; Binley J; Lee J; Barbas CF; Parren PW; Burton DR; Sodroski J J Virol; 1998 Aug; 72(8):6332-8. PubMed ID: 9658072 [TBL] [Abstract][Full Text] [Related]
15. Naturally occurring soluble CD4 in patients with human immunodeficiency virus infection. Peakman M; Senaldi G; Foote N; McManus TJ; Vergani D J Infect Dis; 1992 May; 165(5):799-804. PubMed ID: 1349032 [TBL] [Abstract][Full Text] [Related]
16. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. Kozak SL; Platt EJ; Madani N; Ferro FE; Peden K; Kabat D J Virol; 1997 Feb; 71(2):873-82. PubMed ID: 8995603 [TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells. Valenzuela A; Blanco J; Krust B; Franco R; Hovanessian AG J Virol; 1997 Nov; 71(11):8289-98. PubMed ID: 9343181 [TBL] [Abstract][Full Text] [Related]
18. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Moore JP; McKeating JA; Weiss RA; Sattentau QJ Science; 1990 Nov; 250(4984):1139-42. PubMed ID: 2251501 [TBL] [Abstract][Full Text] [Related]
19. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Bower JF; Green TD; Ross TM Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849 [TBL] [Abstract][Full Text] [Related]
20. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Hwang SS; Boyle TJ; Lyerly HK; Cullen BR Science; 1992 Jul; 257(5069):535-7. PubMed ID: 1636088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]